Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Jun 22, 2020 09:00AM Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway
Jun 18, 2020 09:35PM Form 3 Repare Therapeutics Inc. For: Jun 18 Filed by: ORBIMED ADVISORS LLC
Jun 17, 2020 09:00AM Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer
Jun 11, 2020 04:26PM Form SC 13D/A BELLUS Health Inc. Filed by: ORBIMED ADVISORS LLC
Jun 4, 2020 04:59PM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
May 27, 2020 07:00AM Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
May 26, 2020 04:40PM Form SC 13D/A scPharmaceuticals Inc. Filed by: ORBIMED ADVISORS LLC
May 22, 2020 04:55PM Form SC 13D/A Turning Point Therapeuti Filed by: ORBIMED ADVISORS LLC
May 22, 2020 04:55PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
May 22, 2020 07:00AM Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
May 22, 2020 07:00AM Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
May 20, 2020 05:28PM Form 4 Xtant Medical Holdings, For: May 06 Filed by: ORBIMED ADVISORS LLC
May 20, 2020 04:55PM Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
May 15, 2020 04:37PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 8, 2020 06:01AM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
May 7, 2020 07:00AM 9 Meters Biopharma, Inc Announces the Closing of Naia Rare Diseases Acquisition
May 6, 2020 06:11PM Natera (NTRA) Tops Q1 EPS by 11c, Revenues Beat
May 6, 2020 04:05PM Natera Reports First Quarter 2020 Financial Results
May 4, 2020 05:30PM 9 Meters Biopharma, Inc Announces the Closing of $22.5 Million Private Placement Funding
May 1, 2020 04:16PM Form SC 13D Oric Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Apr 30, 2020 06:15PM 9 Meters Biopharma, a Rare, Orphan and Unmet Needs GI-Focused Company, is Created with the Transformative Merger Between Innovate Biopharmaceuticals and RDD Pharma
Apr 30, 2020 04:29PM Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F
Apr 30, 2020 09:00AM Three Finalists Announced for the 2020 Bloom Burton Award
Apr 29, 2020 07:24AM resTORbio (TORC) and Adicet Bio Announce Merger Agreement
Apr 29, 2020 07:00AM resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
Apr 29, 2020 07:00AM resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
Apr 28, 2020 05:14PM Form 4 Oric Pharmaceuticals, For: Apr 24 Filed by: ORBIMED ADVISORS LLC
Apr 23, 2020 08:28PM Form 3 Oric Pharmaceuticals, For: Apr 23 Filed by: ORBIMED ADVISORS LLC
Apr 22, 2020 01:30AM Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update
Apr 17, 2020 04:14PM Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Apr 17, 2020 04:08PM Form SC 13D Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 17, 2020 06:01AM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 16, 2020 08:24PM Form 4 Alector, Inc. For: Apr 14 Filed by: ORBIMED ADVISORS LLC
Apr 16, 2020 05:00AM Themis Announces Iain Dukes to Join the Company’s Supervisory Board
Apr 9, 2020 04:58PM Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 9, 2020 04:54PM Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 2, 2020 05:07PM Form 4 Alector, Inc. For: Mar 31 Filed by: ORBIMED ADVISORS LLC
Mar 30, 2020 06:07AM Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 30, 2020 06:04AM Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 27, 2020 01:47PM Form SC 13D/A scPharmaceuticals Inc. Filed by: ORBIMED ADVISORS LLC
Mar 26, 2020 08:00AM ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing
Mar 25, 2020 05:55PM Form 4 Alector, Inc. For: Mar 23 Filed by: ORBIMED ADVISORS LLC
Mar 24, 2020 06:06AM Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 24, 2020 06:02AM Form 144 Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 20, 2020 05:30PM Innovate Biopharmaceuticals Announces Full Year 2019 Financial Results And Strategic And Operational Updates
Mar 20, 2020 05:09PM Form SC 13D IMARA Inc. Filed by: ORBIMED ADVISORS LLC
Mar 11, 2020 06:32PM Form 3 IMARA Inc. For: Mar 11 Filed by: ORBIMED ADVISORS LLC
Mar 11, 2020 09:30AM Innovate Biopharmaceuticals Affirms Timeline for Closing of Merger with RDD Pharma Ltd. Closing Expected Around the End of the First Quarter of 2020
Mar 11, 2020 04:30AM Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B Financing
Mar 10, 2020 05:04PM Form SC 13G/A CTI BIOPHARMA CORP Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed